CORV - Correvio Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7300
+0.0300 (+1.11%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.7000
Open2.6562
Bid2.6700 x 800
Ask2.7700 x 900
Day's Range2.6400 - 2.7300
52 Week Range1.9900 - 5.2400
Volume41,396
Avg. Volume169,251
Market Cap110.194M
Beta (3Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.4720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.80
Trade prices are not sourced from all markets
  • ACCESSWIRE13 days ago

    Cannabis Industry Consuming Energy at An Alarming Rate: Investing in Solutions

    HENDERSON, NV / ACCESSWIRE / April 9, 2019 / As per the report, "The Cannabis Energy Report: Current and Evolving State of Cannabis Energy Consumption" published by New Frontier Data, cannabis ...

  • CNW Group19 days ago

    Correvio Announces Zevtera® Abstracts at ECCMID 2019

    Correvio Announces Zevtera® Abstracts at ECCMID 2019

  • CNW Group19 days ago

    Correvio Announces Xydalba™ (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019

    Correvio Announces Xydalba™ (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019

  • CNW Group20 days ago

    Correvio to present at the H.C. Wainwright Global Life Sciences Conference

    Correvio to present at the H.C. Wainwright Global Life Sciences Conference

  • PR Newswirelast month

    Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting

    VANCOUVER, March 20, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March 16-18, 2019, in New Orleans.  This poster presentation highlights reduced hospitalization in patients treated with Brinavess, Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF at the Hillel Yaffe Medical Center located in Hadera, Israel. This presentation, titled "Intravenous Vernakalant for the Treatment of New-Onset Atrial Fibrillation in the Emergency Department," was given by Jameel Mohsen, MD, Hillel Yaffe Medical Center.

  • PR Newswirelast month

    Correvio Announces at the Market Offering

    VANCOUVER, March 14, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), ("Correvio" or the "Company"), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has entered into an At the Market Sales Issuance Agreement dated March 13, 2019 (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") as agent, pursuant to which the Company may, from time to time sell, through "at-the-market" offerings on the Nasdaq Capital Market  or another existing trading market in the United States with Cantor as agent, such number of common shares as would have an aggregate offer price of up to US$50,000,000 subject to a limit of US$12,000,000 under the ATM Prospectus Supplement (as defined below). Cantor, at Correvio's discretion and instruction, will use its commercially reasonable efforts to sell the common shares at market prices from time to time.

  • CNW Grouplast month

    Correvio Reports Fourth Quarter and Full Year 2018 Financial Results

    Correvio Reports Fourth Quarter and Full Year 2018 Financial Results

  • CNW Grouplast month

    Correvio Announces Amendment To Term Loan With CRG-Managed Funds

    VANCOUVER , March 11, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced an amendment to its existing agreement with CRG Servicing LLC ("CRG") dated May 11, 2017 (the "Amending Agreement"), which provides for an increase in capital available to the Company.  Under the terms of the amended agreement, Correvio is now eligible to receive up to an additional $10 million .  Under the Amending Agreement, Correvio will pay a small access fee to CRG.  The additional funding may be drawn at Correvio's discretion in increments of $2.5 million through September 30, 2019 and there will be prepayment premium associated with any such draw-down. "This amended credit facility provides important non-dilutive, near-term capital as well as greater financial flexibility to achieve our corporate objectives this year," said William Hunter , MD, CEO of Correvio.  "Based on our current operating plan, the net proceeds from CRG, combined with our existing cash, provide us with enough capital to get an answer from the U.S. Food and Drug Administration on the Brinavess® New Drug Application which we remain on track to resubmit the Brinavess NDA during the second quarter of 2019.

  • PR Newswire2 months ago

    Correvio to Present at Upcoming Investor Conferences

    NASDAQ: CORV  TSX: CORV VANCOUVER , March 7, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced ...

  • PR Newswire2 months ago

    Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019

    NASDAQ: CORV  TSX: CORV Conference Call Scheduled for Wednesday,  March 13, 2019 at 8:00 a.m. Eastern ( 5:00 a.m. Pacific) VANCOUVER , March 6, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / ...

  • CNW Group2 months ago

    Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

    Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

  • CNW Group2 months ago

    Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress

    VANCOUVER , Feb. 7, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlighting the low  rate of hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), at the Belgian Society of Cardiology (BSC) 2019 Annual Congress, being held Feb 7-8, 2019 in Brussels , Belgium. The presentation will include data from a clinical survey assessing patients with acute AF treated with Brinavess in Belgian hospitals. The data from this survey, which was mandated by Belgium's National Institute for Health and Disability Insurance (NIHDI), was provided by six participating hospitals, enrolling a total of 97 patients that were treated with Brinavess in the emergency room setting over a 15.5-month period during 2017 and 2018.

  • PR Newswire3 months ago

    Correvio Provides Update On At The Market Offering

    VANCOUVER, Jan. 17, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the completion of sales of all common shares qualified under its ATM Prospectus Supplement (defined below). The Company's at-the-market sales issuance agreement, dated July 10, 2018, between the Company and B.Riley FBR, Inc., as agent, continues in force.